The conferences will take place on Monday, March 2, 2015 in Boston and Tuesday, March 10, 2015 in Miami
Boston, MA – February 23, 2015 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced that its management team will participate in two upcoming investor conferences. Details of the conferences are as follows:
Cowen & Co. 35th Annual Health Care Conference in Boston, MA. Travis Wilson, Stealth’s Chief Executive Officer, will present a corporate overview on Monday, March 2, 2015 at 3:00 p.m. EST at the Boston Marriott Copley Place.
2015 Barclays Global Healthcare Conference in Miami, FL. The management team will provide a company update to investors on Tuesday, March 10, 2015 at the Loews Miami Beach Hotel.
Stealth BioTherapeutics: Leading Mitochondrial Medicine
Stealth BioTherapeutics is a privately-held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria — the cell’s energy source — offer a promising, and yet untapped, target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.
More information regarding Stealth and its pipeline is available at www.stealthBT.com.
Phone: (617) 520-7018
Phone: (212) 362-1200